Literature DB >> 27218485

Contribution of peripheral and central chemoreceptors to sympatho-excitation in heart failure.

Camilo Toledo1, David C Andrade1, Claudia Lucero1, Harold D Schultz2, Noah Marcus3, Mauricio Retamal4, Carlos Madrid4, Rodrigo Del Rio1.   

Abstract

Chronic heart failure (CHF) is a major public health problem. Tonic hyper-activation of sympathetic neural outflow is commonly observed in patients with CHF. Importantly, sympatho-excitation in CHF exacerbates its progression and is strongly related to poor prognosis and high mortality risk. Increases in both peripheral and central chemoreflex drive are considered markers of the severity of CHF. The principal peripheral chemoreceptors are the carotid bodies (CBs) and alteration in their function has been described in CHF. Mainly, during CHF the CB chemosensitivity is enhanced leading to increases in ventilation and sympathetic outflow. In addition to peripheral control of breathing, central chemoreceptors (CCs) are considered a dominant mechanism in ventilatory regulation. Potentiation of the ventilatory and sympathetic drive in response to CC activation has been shown in patients with CHF as well as in animal models. Therefore, improving understanding of the contribution of the peripheral and central chemoreflexes to augmented sympathetic discharge in CHF could help in developing new therapeutic approaches intended to attenuate the progression of CHF. Accordingly, the main focus of this review is to discuss recent evidence that peripheral and central chemoreflex function are altered in CHF and that they contribute to autonomic imbalance and progression of CHF.
© 2016 The Authors. The Journal of Physiology © 2016 The Physiological Society.

Entities:  

Mesh:

Year:  2016        PMID: 27218485      PMCID: PMC5199744          DOI: 10.1113/JP272075

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  89 in total

1.  Guidelines for the diagnosis and treatment of chronic heart failure.

Authors:  W J Remme; K Swedberg
Journal:  Eur Heart J       Date:  2001-09       Impact factor: 29.983

2.  Hypoxia silences retrotrapezoid nucleus respiratory chemoreceptors via alkalosis.

Authors:  Tyler M Basting; Peter G R Burke; Roy Kanbar; Kenneth E Viar; Daniel S Stornetta; Ruth L Stornetta; Patrice G Guyenet
Journal:  J Neurosci       Date:  2015-01-14       Impact factor: 6.167

3.  Differential role of the paraventricular nucleus of the hypothalamus in modulating the sympathoexcitatory component of peripheral and central chemoreflexes.

Authors:  Maram K Reddy; Kaushik P Patel; Harold D Schultz
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2005-05-26       Impact factor: 3.619

4.  Angiotensin II enhances carotid body chemoreflex control of sympathetic outflow in chronic heart failure rabbits.

Authors:  Yu-Long Li; Xiao-Hong Xia; Hong Zheng; Lie Gao; Yi-Fan Li; Dongmei Liu; Kaushik P Patel; Wei Wang; Harold D Schultz
Journal:  Cardiovasc Res       Date:  2006-03-24       Impact factor: 10.787

5.  Inhibition of hydrogen sulfide restores normal breathing stability and improves autonomic control during experimental heart failure.

Authors:  Rodrigo Del Rio; Noah J Marcus; Harold D Schultz
Journal:  J Appl Physiol (1985)       Date:  2013-02-28

6.  NADPH oxidase-derived superoxide anion mediates angiotensin II-enhanced carotid body chemoreceptor sensitivity in heart failure rabbits.

Authors:  Yu-Long Li; Lie Gao; Irving H Zucker; Harold D Schultz
Journal:  Cardiovasc Res       Date:  2007-04-19       Impact factor: 10.787

Review 7.  Adrenergic nervous system in heart failure: pathophysiology and therapy.

Authors:  Anastasios Lymperopoulos; Giuseppe Rengo; Walter J Koch
Journal:  Circ Res       Date:  2013-08-30       Impact factor: 17.367

8.  Connexin hemichannel-mediated CO2-dependent release of ATP in the medulla oblongata contributes to central respiratory chemosensitivity.

Authors:  Robert T R Huckstepp; Rachid id Bihi; Robert Eason; K Michael Spyer; Nikolai Dicke; Klaus Willecke; Nephtali Marina; Alexander V Gourine; Nicholas Dale
Journal:  J Physiol       Date:  2010-08-24       Impact factor: 5.182

Review 9.  Mechanisms of carotid body chemoreflex dysfunction during heart failure.

Authors:  Harold D Schultz; Noah J Marcus; Rodrigo Del Rio
Journal:  Exp Physiol       Date:  2015-01-15       Impact factor: 2.969

Review 10.  Selective carotid body ablation in experimental heart failure: a new therapeutic tool to improve cardiorespiratory control.

Authors:  Rodrigo Del Rio; David C Andrade; Noah J Marcus; Harold D Schultz
Journal:  Exp Physiol       Date:  2015-01-06       Impact factor: 2.969

View more
  15 in total

Review 1.  Revisiting the physiological effects of exercise training on autonomic regulation and chemoreflex control in heart failure: does ejection fraction matter?

Authors:  David C Andrade; Alexis Arce-Alvarez; Camilo Toledo; Hugo S Díaz; Claudia Lucero; Rodrigo A Quintanilla; Harold D Schultz; Noah J Marcus; Markus Amann; Rodrigo Del Rio
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-11-22       Impact factor: 4.733

2.  Carotid chemoreceptors tune breathing via multipath routing: reticular chain and loop operations supported by parallel spike train correlations.

Authors:  Kendall F Morris; Sarah C Nuding; Lauren S Segers; Kimberly E Iceman; Russell O'Connor; Jay B Dean; Mackenzie M Ott; Pierina A Alencar; Dale Shuman; Kofi-Kermit Horton; Thomas E Taylor-Clark; Donald C Bolser; Bruce G Lindsey
Journal:  J Neurophysiol       Date:  2017-10-18       Impact factor: 2.714

3.  Role of A5 noradrenergic neurons in the chemoreflex control of respiratory and sympathetic activities in unanesthetized conditions.

Authors:  Camila L Taxini; Thiago S Moreira; Ana C Takakura; Kênia C Bícego; Luciane H Gargaglioni; Daniel B Zoccal
Journal:  Neuroscience       Date:  2017-04-29       Impact factor: 3.590

4.  Cardiac diastolic and autonomic dysfunction are aggravated by central chemoreflex activation in heart failure with preserved ejection fraction rats.

Authors:  Camilo Toledo; David C Andrade; Claudia Lucero; Alexis Arce-Alvarez; Hugo S Díaz; Valentín Aliaga; Harold D Schultz; Noah J Marcus; Mónica Manríquez; Marcelo Faúndez; Rodrigo Del Rio
Journal:  J Physiol       Date:  2017-03-19       Impact factor: 5.182

5.  The exercise pressor reflex and chemoreflex interaction: cardiovascular implications for the exercising human.

Authors:  Hsuan-Yu Wan; Joshua C Weavil; Taylor S Thurston; Vincent P Georgescu; Thomas J Hureau; Amber D Bledsoe; Michael J Buys; Jacob E Jessop; Russell S Richardson; Markus Amann
Journal:  J Physiol       Date:  2020-04-27       Impact factor: 5.182

6.  Targeting autonomic imbalance in pathophysiology: is the carotid body the new nirvana?

Authors:  Julian F R Paton
Journal:  J Physiol       Date:  2017-01-01       Impact factor: 5.182

Review 7.  Carotid body chemoreceptors: physiology, pathology, and implications for health and disease.

Authors:  Rodrigo Iturriaga; Julio Alcayaga; Mark W Chapleau; Virend K Somers
Journal:  Physiol Rev       Date:  2021-02-11       Impact factor: 46.500

8.  Hypercapnia elicits differential vascular and blood flow responses in the cerebral circulation and active skeletal muscles in exercising humans.

Authors:  Shodai Moriyama; Masashi Ichinose; Kohei Dobashi; Ryoko Matsutake; Mizuki Sakamoto; Naoto Fujii; Takeshi Nishiyasu
Journal:  Physiol Rep       Date:  2022-04

9.  Carotid Body-Mediated Chemoreflex Drive in The Setting of low and High Output Heart Failure.

Authors:  Rodrigo Del Rio; David C Andrade; Camilo Toledo; Hugo S Diaz; Claudia Lucero; Alexis Arce-Alvarez; Noah J Marcus; Harold D Schultz
Journal:  Sci Rep       Date:  2017-08-14       Impact factor: 4.379

10.  Exercise intolerance in volume overload heart failure is associated with low carotid body mediated chemoreflex drive.

Authors:  David C Andrade; Esteban Díaz-Jara; Camilo Toledo; Karla G Schwarz; Katherin V Pereyra; Hugo S Díaz; Noah J Marcus; Fernando C Ortiz; Angélica P Ríos-Gallardo; Domiziana Ortolani; Rodrigo Del Rio
Journal:  Sci Rep       Date:  2021-07-14       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.